Get the Stockscreener App
58.54
0.26%
-0.15
Catalent Inc stock is traded at $58.54, with a volume of 858.22K.
It is down -0.26% in the last 24 hours and down -3.38% over the past month.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
See More
Previous Close:
$58.69
Open:
$58.5
24h Volume:
858.22K
Relative Volume:
0.57
Market Cap:
$10.65B
Revenue:
$4.38B
Net Income/Loss:
$-1.04B
P/E Ratio:
-45.03
EPS:
-1.3
Net Cash Flow:
$-59.00M
1W Performance:
-0.20%
1M Performance:
-3.38%
6M Performance:
+3.61%
1Y Performance:
+65.98%
1-Day Range:
$58.30
$58.92
1-Week Range:
$58.30
$59.25
52-Week Range:
$32.38
$61.20
Catalent Inc Stock (CTLT) Company Profile
Name
Catalent Inc
Sector
Phone
(732) 537-6200
Address
14 SCHOOLHOUSE ROAD, SOMERSET, NJ
Catalent Inc Stock (CTLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-16-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-05-23 | Upgrade | Argus | Hold → Buy |
| Jul-20-23 | Initiated | Wells Fargo | Equal Weight |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jun-14-23 | Downgrade | Jefferies | Buy → Hold |
| May-22-23 | Downgrade | JP Morgan | Overweight → Neutral |
| May-15-23 | Downgrade | Deutsche Bank | Buy → Hold |
| May-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-17-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Nov-07-22 | Downgrade | Argus | Buy → Hold |
| Nov-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-16-21 | Initiated | Barclays | Overweight |
| Dec-10-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jun-25-20 | Initiated | Argus | Buy |
| Apr-21-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Oct-17-19 | Resumed | Stephens | Overweight |
| Aug-28-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jun-21-19 | Upgrade | Jefferies | Hold → Buy |
| Apr-16-19 | Upgrade | UBS | Neutral → Buy |
| Nov-07-18 | Upgrade | First Analysis Sec | Neutral → Outperform |
| Oct-09-18 | Initiated | UBS | Neutral |
| Mar-28-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-21-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-06-18 | Downgrade | Stephens | Overweight → Equal-Weight |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-17 | Initiated | Needham | Hold |
| Sep-08-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
| Dec-01-16 | Initiated | Goldman | Neutral |
| Oct-20-16 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jun-21-16 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jun-20-16 | Upgrade | BofA/Merrill | Neutral → Buy |
View All
Catalent Inc Stock (CTLT) Latest News
Novo Holdings Acquires Catalent Despite Financial Setback - Finimize
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings - Reuters
Catalent: Fiscal Q1 Earnings Snapshot - San Francisco Chronicle
Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings - Yahoo Finance
Catalent Inc earnings missed by $0.16, revenue fell short of estimates - Investing.com Canada
Catalent reports Q1 EPS (13c), consensus 5c - TipRanks
Catalent, Inc. Reports First Quarter Fiscal 2025 Results - Business Wire
Life Sciences BPO Market Set to Witness Significant Growth by 2024-2031:Catalent, Inc., Covance, Inc., Fareva, - EIN News
Commit To Buy Catalent At $55, Earn 1.5% Annualized Using Options - Nasdaq
EU antitrust regulators to rule on Novo's Catalent buy by Dec. 6 - Yahoo Finance
Assenagon Asset Management S.A. Has $330,000 Position in Catalent, Inc. (NYSE:CTLT) - MarketBeat
EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6 - Marketscreener.com
Catalent Acquisition By Novo Holdings: Evolution Of The Industry(?) - Contract Pharma
Americana Partners LLC Buys New Shares in Catalent, Inc. (NYSE:CTLT) - MarketBeat
Catalent, Inc. (NYSE:CTLT) Shares Sold by Norris Perne & French LLP MI - MarketBeat
Forsta AP Fonden Grows Holdings in Catalent, Inc. (NYSE:CTLT) - MarketBeat
Catalent to sell New Jersey drug facility to Ardena - Yahoo Finance
Backlash builds against Novo’s Catalent takeover - Yahoo Finance
Summer 2025: Intern, Downstream Process Development - Built In
Catalent : IsomAb Announces Strategic Collaboration with Catalent - Marketscreener.com
What to Expect From Catalent's Next Quarterly Earnings Report - MSN
What To Expect From Catalent's Next Quarterly Earnings Report - Barchart
Catalent Analysts Raise Their Forecasts Following Acquisition News - MSN
Summer 2025: InternEngineering - Built In
9,631 Shares in Catalent, Inc. (NYSE:CTLT) Acquired by Legacy Capital Group California Inc. - MarketBeat
Summer 2025: Intern, Project Management - Built In
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’ - BioSpace
Consumer groups ask FTC to block Novo Holdings-Catalent deal - MSN
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition - Yahoo Finance
Roche CEO Says Novo-Catalent Deal Should Be Blocked - Law360
Roche comes out against allowing takeover of drug manufacturer Catalent - Yahoo Finance
Roche CEO says antitrust regulators should block Catalent sale to Novo Holdings (update) - Seeking Alpha
Roche comes out against clearing takeover of drug manufacturer Catalent - Marketscreener.com
Catalent rebukes vertical foreclosure concerns - Global Competition Review
Catalent SVP sells shares worth $19,190 By Investing.com - Investing.com South Africa
Catalent SVP sells shares worth $19,190 - Investing.com India
Catalent CEO affirms commitment post Novo Holdings acquisition By Investing.com - Investing.com Canada
Catalent, Inc. (NYSE:CTLT) SVP Joseph Anthony Ferraro Sells 320 Shares - MarketBeat
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout - Reuters
Catalent CEO Defends Novo Deal, Will Stay On After Buyout - Law360
Catalent, Inc. (CTLT) Issues Open Letter to Customers - GuruFocus.com
Catalent CEO Assures Continuity After Novo Holdings Buyout: Retail Investors Wait And Watch - Barchart
Catalent CEO affirms commitment post Novo Holdings acquisition - Investing.com India
Catalent Inc Stock (CTLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.26%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):